Loading...
XNASHBIO
Market cap90mUSD
Dec 24, Last price  
2.08USD
1D
-0.95%
1Q
-21.80%
Jan 2017
-31.80%
IPO
-52.29%
Name

Harvard Bioscience Inc

Chart & Performance

D1W1MN
XNAS:HBIO chart
P/E
P/S
0.81
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
3.08%
Rev. gr., 5y
-1.45%
Revenues
112m
-0.96%
92,597,00067,431,00076,181,00083,407,00088,049,00085,772,000108,179,000108,864,000111,171,000105,171,000108,663,000108,664,000104,521,000101,882,000120,774,000116,176,000102,100,000118,904,000113,335,000112,250,000
Net income
-3m
L-64.11%
2,329,000-31,877,000-2,341,000-1,354,0001,673,0007,233,00019,015,0003,812,0002,370,000-1,830,0002,355,000-19,039,000-4,307,000-865,000-3,462,000-4,687,000-7,810,000-288,000-9,516,000-3,415,000
CFO
14m
+1,117.71%
11,438,0005,195,0008,356,00012,055,0009,202,00016,509,00012,293,0006,348,0008,062,0004,060,0004,351,000705,0005,383,0001,057,0002,344,0008,047,0009,331,0001,262,0001,152,00014,028,000
Earnings
Mar 05, 2025

Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
IPO date
Oct 21, 2013
Employees
436
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
112,250
-0.96%
113,335
-4.68%
118,904
16.46%
Cost of revenue
104,831
114,379
110,998
Unusual Expense (Income)
NOPBT
7,419
(1,044)
7,906
NOPBT Margin
6.61%
6.65%
Operating Taxes
859
337
148
Tax Rate
11.58%
1.87%
NOPAT
6,560
(1,381)
7,758
Net income
(3,415)
-64.11%
(9,516)
3,204.17%
(288)
-96.31%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,051)
(200)
BB yield
0.92%
0.07%
Debt
Debt current
8,691
3,811
3,235
Long-term debt
41,708
50,430
53,725
Deferred revenue
(1,558)
Other long-term liabilities
1,476
6,288
8,532
Net debt
46,116
50,066
50,697
Cash flow
Cash from operating activities
14,028
1,152
1,262
CAPEX
(1,788)
(1,590)
(1,345)
Cash from investing activities
(1,799)
(1,590)
(1,345)
Cash from financing activities
(12,134)
(2,837)
(252)
FCF
1,446
3,171
673
Balance
Cash
4,283
4,508
7,821
Long term investments
(333)
(1,558)
Excess cash
318
Stockholders' equity
(159,361)
(156,788)
(142,249)
Invested Capital
278,100
282,120
280,730
ROIC
2.34%
2.77%
ROCE
6.21%
5.65%
EV
Common stock shares outstanding
42,420
41,413
40,343
Price
5.35
93.14%
2.77
-60.71%
7.05
64.34%
Market cap
226,947
97.84%
114,714
-59.67%
284,418
71.58%
EV
273,063
164,780
335,115
EBITDA
14,417
6,531
15,527
EV/EBITDA
18.94
25.23
21.58
Interest
3,591
2,246
1,540
Interest/NOPBT
48.40%
19.48%